HK1107672A1 - Conveniently implantable sustained release drug compositions - Google Patents
Conveniently implantable sustained release drug compositionsInfo
- Publication number
- HK1107672A1 HK1107672A1 HK07113369.9A HK07113369A HK1107672A1 HK 1107672 A1 HK1107672 A1 HK 1107672A1 HK 07113369 A HK07113369 A HK 07113369A HK 1107672 A1 HK1107672 A1 HK 1107672A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sustained release
- release drug
- drug compositions
- implantable sustained
- conveniently
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Oral & Maxillofacial Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61448404P | 2004-10-01 | 2004-10-01 | |
US70966505P | 2005-08-19 | 2005-08-19 | |
PCT/US2005/034822 WO2006039336A2 (fr) | 2004-10-01 | 2005-09-27 | Compositions de medicament a liberation soutenue pouvant etre implantees de facon appropriee |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1107672A1 true HK1107672A1 (en) | 2008-04-11 |
Family
ID=36143017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07113369.9A HK1107672A1 (en) | 2004-10-01 | 2007-12-06 | Conveniently implantable sustained release drug compositions |
Country Status (13)
Country | Link |
---|---|
US (1) | US7906136B2 (fr) |
EP (3) | EP1793803B1 (fr) |
JP (6) | JP5682991B2 (fr) |
KR (2) | KR101506925B1 (fr) |
CN (2) | CN101890167B (fr) |
AU (2) | AU2005292145C1 (fr) |
BR (1) | BRPI0516830A (fr) |
CA (1) | CA2582096C (fr) |
HK (1) | HK1107672A1 (fr) |
MX (3) | MX344532B (fr) |
MY (1) | MY167123A (fr) |
NZ (1) | NZ554426A (fr) |
WO (1) | WO2006039336A2 (fr) |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
US7585517B2 (en) * | 2003-09-18 | 2009-09-08 | Macusight, Inc. | Transscleral delivery |
US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
WO2006078320A2 (fr) | 2004-08-04 | 2006-07-27 | Brookwood Pharmaceuticals, Inc. | Procede de production de systemes d'administration, et systemes d'administration |
US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
JP5089397B2 (ja) | 2004-11-22 | 2012-12-05 | サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィク | 変異ネトリン4、その断片及びこれらの薬剤としての使用 |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
EP1848431B1 (fr) * | 2005-02-09 | 2016-02-03 | Santen Pharmaceutical Co., Ltd. | Formulations liquides pour le traitement de maladies ou affections |
US7592330B2 (en) * | 2005-08-08 | 2009-09-22 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
US9301919B2 (en) * | 2005-12-22 | 2016-04-05 | Oakwood Laboratories, Llc | Sublimable sustained release delivery system and method of making same |
US7756524B1 (en) | 2006-01-31 | 2010-07-13 | Nextel Communications Inc. | System and method for partially count-based allocation of vocoder resources |
WO2009113972A2 (fr) | 2006-02-08 | 2009-09-17 | Tyrx Pharma, Inc. | Prothèses de type treillis temporairement raidies |
US8591531B2 (en) | 2006-02-08 | 2013-11-26 | Tyrx, Inc. | Mesh pouches for implantable medical devices |
WO2007092620A2 (fr) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Formulations stables et leurs procedes de preparation et d'utilisation |
WO2007100609A2 (fr) * | 2006-02-24 | 2007-09-07 | Albert Einstein College Of Medicine Of Yeshiva University | Transfert d'electrons par des matrices vitreuses |
PL2001466T3 (pl) * | 2006-03-23 | 2016-06-30 | Santen Pharmaceutical Co Ltd | Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń |
US20070265329A1 (en) * | 2006-05-12 | 2007-11-15 | Devang Shah T | Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) |
PL1864667T3 (pl) * | 2006-06-01 | 2014-01-31 | Santen Sas | Zastosowanie proleków do podania do ciała szklistego oka |
AU2007284759B2 (en) | 2006-08-09 | 2010-10-28 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
RU2009110257A (ru) * | 2006-08-23 | 2010-09-27 | Новартис АГ (CH) | Применение ингибиторов ркс, прежде всего производных индолилмалеимида для лечения глазных заболеваний |
WO2008033924A2 (fr) * | 2006-09-12 | 2008-03-20 | Board Of Regents Of The University Of Nebraska | Méthodes et compositions pour l'administration ciblée d'agents thérapeutiques |
US20080138350A1 (en) * | 2006-10-20 | 2008-06-12 | Bennett Michael D | Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery |
EP2236546B1 (fr) * | 2006-10-31 | 2011-12-28 | Surmodics Pharmaceuticals, Inc. | Particules polymères mises sous forme de sphères |
US9023114B2 (en) | 2006-11-06 | 2015-05-05 | Tyrx, Inc. | Resorbable pouches for implantable medical devices |
MY148370A (en) | 2006-12-18 | 2013-04-15 | Takeda Pharmaceutical | Sustained-release composition and method for producing the same |
PT2481409T (pt) * | 2007-03-07 | 2018-10-18 | Abraxis Bioscience Llc | Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
US20080317805A1 (en) * | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
AU2008271911B2 (en) * | 2007-06-29 | 2014-08-07 | Phovitreal Pty Ltd | Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration |
KR100882817B1 (ko) * | 2007-07-20 | 2009-02-10 | 숙명여자대학교산학협력단 | 보툴리늄 독소를 유효성분으로 포함하는 지방세포 생착증진용 약학적 조성물 |
US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
WO2009076369A1 (fr) * | 2007-12-10 | 2009-06-18 | The Trustees Of The University Of Pennsylvania | Matrices à base de chitosane et leurs utilisations |
JP5502751B2 (ja) | 2007-12-20 | 2014-05-28 | エボニック コーポレイション | 低残留溶媒濃度を有する微粒子を調製するためのプロセス |
US20110104253A1 (en) | 2008-01-18 | 2011-05-05 | Horst Kief | Agent for intra-articular injection |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
US20090226547A1 (en) * | 2008-03-05 | 2009-09-10 | Gilbard Jeffrey P | Dietary Supplement For Eye Health |
US9125917B2 (en) * | 2008-04-18 | 2015-09-08 | Warsaw Orthopedic, Inc. | Fluocinolone formulations in a biodegradable polymer carrier |
US9132119B2 (en) * | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
US8883768B2 (en) * | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
WO2010009291A1 (fr) * | 2008-07-16 | 2010-01-21 | Surmodics Pharmaceuticals, Inc. | Procédé pour préparer des microparticules contenant des peptides bioactifs |
US8697155B2 (en) * | 2008-07-22 | 2014-04-15 | Mayo Foundation For Medical Education And Research | Treatment of obesity and related disorders |
CN102164943A (zh) * | 2008-09-24 | 2011-08-24 | 稳定技术有限公司 | 使用糖和聚乙烯亚胺保存多肽的方法 |
US20110212127A1 (en) * | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
EP2350012B1 (fr) * | 2008-10-06 | 2017-06-28 | The Johns Hopkins University | Composés de quinoline en tant qu'inhibiteurs de l'angiogenèse, de la méthionine aminopeptidase humaine et de la sirt1, et méthodes de traitement de troubles |
CN102238949A (zh) | 2008-10-09 | 2011-11-09 | 拉姆斯科股份有限公司 | 治疗干眼综合征的组合物和方法 |
CN102365109B (zh) | 2009-01-29 | 2015-06-03 | 弗赛特影像4股份有限公司 | 后段给药 |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
WO2011031476A2 (fr) * | 2009-08-25 | 2011-03-17 | Emory University | Compositions et méthodes pour le traitement ou la prévention d'une inflammation post-opératoire d'un organe ou d'un tissu |
MX352878B (es) | 2009-09-28 | 2017-12-13 | Intarcia Therapeutics Inc | Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco. |
US20110097380A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Clonidine formulations having antimicrobial properties |
WO2013022801A1 (fr) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable |
ES2708989T3 (es) | 2010-03-31 | 2019-04-12 | Stabilitech Biopharma Ltd | Método de conservación de adyuvantes de alumbre y vacunas potenciadas con alumbre |
DK2552478T3 (en) | 2010-03-31 | 2017-03-27 | Stabilitech Ltd | EXCIPIENTS FOR STABILIZING VIRUS PARTICLES |
GB2499479A (en) | 2010-03-31 | 2013-08-21 | Stabilitech Ltd | Stabilisation of viral particles |
DE102010013898A1 (de) * | 2010-04-01 | 2011-10-06 | Acino Ag | Implantatskanüle mit Implantat und Verfahren zum Befestigen von Implantaten in einer Injektionskanüle |
HUE057267T2 (hu) | 2010-08-05 | 2022-05-28 | Forsight Vision4 Inc | Berendezés szem kezelésére |
WO2012019139A1 (fr) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Procédés et appareils d'administration combinée de médicament |
JP6063382B2 (ja) | 2010-08-05 | 2017-01-18 | フォーサイト・ビジョン フォー・インコーポレーテッド | 治療薬を眼の埋め込み体へと注入するためのシステム |
CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2012097258A2 (fr) * | 2011-01-15 | 2012-07-19 | The Regents Of The University Of California | Formulations destinées à la prévention et au traitement d'une maladie liée aux wolbachia |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
DK2717914T3 (da) * | 2011-06-10 | 2020-01-20 | Ramscor Inc | Depotformuleringer til administration af proteiner til øjet og fremgangsmåder til fremstilling deraf |
WO2013003620A2 (fr) | 2011-06-28 | 2013-01-03 | Forsight Vision4, Inc. | Procédés et appareil de diagnostic |
PT2755600T (pt) | 2011-09-16 | 2021-04-19 | Forsight Vision4 Inc | Aparelhos de troca de fluidos |
GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
US20130190839A1 (en) * | 2012-01-20 | 2013-07-25 | Jane Rapsey | Drug delivery using a sacrificial host |
WO2013116061A1 (fr) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Procédés et instrument pour l'insertion et le retrait de dispositifs thérapeutiques |
CA2871778C (fr) | 2012-05-03 | 2022-09-13 | Kala Pharmaceuticals, Inc. | Nanoparticules pharmaceutiques permettant un transport muqueux ameliore |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
KR102154880B1 (ko) | 2012-05-03 | 2020-09-10 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
US20140105956A1 (en) * | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
CN105164204A (zh) | 2012-11-21 | 2015-12-16 | 路易斯维尔大学研究基金会 | 用于降低氧化损伤的组合物和方法 |
KR20150096433A (ko) | 2012-12-21 | 2015-08-24 | 사노피 | 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제 |
US9283231B2 (en) | 2013-01-31 | 2016-03-15 | Icon Bioscience, Inc. | Sustained release formulations for the treatment of intraocular pressure of glaucoma |
CA2900652C (fr) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Composes therapeutiques et utilisations de ceux-ci |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
JP6385423B2 (ja) | 2013-03-28 | 2018-09-05 | フォーサイト・ビジョン フォー・インコーポレーテッド | 治療物質送達用の眼移植片 |
WO2014167327A1 (fr) * | 2013-04-09 | 2014-10-16 | Cresset Biomolecular Discovery Ltd | Traitement de troubles inflammatoires |
EP3003318B1 (fr) * | 2013-05-24 | 2021-12-22 | Icon Bioscience, Inc. | Utilisation de la déxaméthasone à libération prolongée dans une inflammation après une chirurgie de la cataracte |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3080149A1 (fr) | 2013-12-13 | 2016-10-19 | Sanofi | Agonistes mixtes des récepteurs du glp-1/glucagon |
EP3080152A1 (fr) | 2013-12-13 | 2016-10-19 | Sanofi | Analogues peptidiques de l'exendine 4 non acylés |
EP3080154B1 (fr) | 2013-12-13 | 2018-02-07 | Sanofi | Agonistes doubles du récepteur glp-1/gip |
EP3080150B1 (fr) | 2013-12-13 | 2018-08-01 | Sanofi | Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double |
WO2015095391A1 (fr) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Comprimé extrudé anti-abus à libération prolongée |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
WO2015158823A1 (fr) | 2014-04-16 | 2015-10-22 | Veyx-Pharma Gmbh | Composition pharmaceutique vétérinaire et utilisation de ladite composition pharmaceutique vétérinaire |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
MY182497A (en) | 2014-07-15 | 2021-01-25 | Forsight Vision4 Inc | Ocular implant delivery device and method |
JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
ES2835499T3 (es) * | 2014-07-30 | 2021-06-22 | Massachusetts Eye & Ear Infirmary | Metotrexato para la vitreorretinopatía proliferativa |
AU2015301054B2 (en) | 2014-08-08 | 2020-05-14 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
EP3180026A4 (fr) * | 2014-08-15 | 2018-04-11 | Pixarbio Corporation | Compositions pour inhiber une inflammation chez un sujet présentant une lésion de la moelle épinière, et procédés d'utilisation de ces compositions |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
EP3256136A4 (fr) | 2015-02-09 | 2018-11-21 | University Of Louisville Research Foundation, Inc. | Compositions ophtalmiques et procédés de réduction des dommages oxydatifs d'un cristallin oculaire |
KR20230104762A (ko) * | 2015-03-18 | 2023-07-10 | 산텐 세이야꾸 가부시키가이샤 | 서방성 의약 조성물 |
CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除系统 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
CN105496947A (zh) * | 2015-11-19 | 2016-04-20 | 苏州桓晨医疗科技有限公司 | 一种药物缓释制剂 |
KR20180084104A (ko) | 2015-11-20 | 2018-07-24 | 포사이트 비젼4, 인크. | 연장 방출 약물 전달 장치를 위한 다공성 구조물 |
MX2018012021A (es) | 2016-04-05 | 2019-01-24 | Forsight Vision4 Inc | Dispositivos de administracion de farmacos oculares implantables. |
MX2018014016A (es) | 2016-05-16 | 2019-08-01 | Intarcia Therapeutics Inc | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10906969B2 (en) | 2016-06-13 | 2021-02-02 | Massachusetts Eye And Ear Infirmary | Local orbital therapy for thyroid eye disease |
US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
EP3478285A4 (fr) | 2016-06-30 | 2020-07-22 | Durect Corporation | Formulations de dépôt |
WO2018048750A1 (fr) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Formes cristallines de composés thérapeutiques et leurs utilisations |
EP3509421A4 (fr) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Formes cristallines de composés thérapeutiques et leurs utilisations |
EP3509422A4 (fr) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Formes cristallines de composés thérapeutiques et leurs utilisations |
CN109803673A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 非蛋白质梭菌毒素组合物 |
EP3565580B1 (fr) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Administration continue d' exénatide et la co-adminstration d' acétaminophène, éthinylestradiol ou lévonorgestrel |
GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
CA3082891A1 (fr) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Appareil d'echange de fluide pour systeme d'administration a port extensible et methodes d'utilisation |
JP7257342B2 (ja) | 2018-02-08 | 2023-04-13 | テルモ株式会社 | 医療器具およびこれを用いた癒合促進デバイス |
US11065003B2 (en) | 2018-03-19 | 2021-07-20 | Terumo Kabushiki Kaisha | Treatment method for joining biological organs |
BR112020022083A2 (pt) * | 2018-05-01 | 2021-02-02 | Chibi, Inc. | depot líquido, estojo e método para tratar a retina. |
KR20210003877A (ko) | 2018-05-01 | 2021-01-12 | 치비 인코포레이티드 | 약제를 눈에 비침습적으로 지속 전달하기 위한 액체 데포 |
JP7361041B2 (ja) | 2018-09-27 | 2023-10-13 | テルモ株式会社 | 癒合促進デバイスおよび医療デバイス |
EP3845149A4 (fr) | 2018-09-27 | 2021-10-27 | TERUMO Kabushiki Kaisha | Dispositif favorisant l'adhérence |
WO2020196887A1 (fr) | 2019-03-28 | 2020-10-01 | テルモ株式会社 | Dispositif médical |
WO2020196885A1 (fr) | 2019-03-28 | 2020-10-01 | テルモ株式会社 | Dispositif médical |
EP3932365A4 (fr) | 2019-03-28 | 2022-05-04 | TERUMO Kabushiki Kaisha | Dispositif de promotion de fusion |
JP7410131B2 (ja) | 2019-03-28 | 2024-01-09 | テルモ株式会社 | 癒合促進デバイス |
US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
CN113262302B (zh) * | 2020-02-17 | 2022-12-09 | 湖州惠中济世生物科技有限公司 | 可注射长效半固体凝胶制剂 |
FI20215186A1 (en) * | 2021-02-19 | 2022-08-20 | Rebio Tech Oy | Compositions for ophthalmic treatment |
US11197819B1 (en) * | 2021-04-09 | 2021-12-14 | Drug Delivery Company, Llc | Extended release bioabsorbable subcutaneous medicinal dosage delivery implant system |
CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
CN117897180A (zh) | 2021-09-03 | 2024-04-16 | 泰尔茂株式会社 | 医疗用部件 |
US11602516B1 (en) | 2022-01-29 | 2023-03-14 | Resurge Therapeutics Inc. | Treating benign prostatic hyperplasia |
US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3119739A (en) | 1961-05-03 | 1964-01-28 | Wanda L Campbell | Acetylmethyl-salicylate for pain relief |
US4126681A (en) | 1975-12-08 | 1978-11-21 | The Procter & Gamble Company | Topical composition containing acetyl salicylic acid |
US4096271A (en) * | 1977-08-03 | 1978-06-20 | American Cyanamid Company | Slow release injectable formulations of tetramisole and derivatives in benzyl benzoate |
US4244948A (en) | 1979-05-07 | 1981-01-13 | Allergan Pharmaceuticals, Inc. | Medical use of esters of acetylsalicylic acid to treat acne |
US4568547A (en) | 1979-08-30 | 1986-02-04 | Herschler R J | Solid pharmaceutical compositions comprising MSM and their production |
US4309996A (en) * | 1980-04-28 | 1982-01-12 | Alza Corporation | System with microporous releasing diffusor |
US4304765A (en) * | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
US4454122A (en) | 1981-04-27 | 1984-06-12 | Bioresearch S.R.L. | Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle |
JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
JPH0662441B2 (ja) * | 1986-02-18 | 1994-08-17 | 花王株式会社 | 抗腫瘍物質徐放性製剤 |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
NZ237084A (en) * | 1990-02-12 | 1993-10-26 | Lucky Ltd | Composition for the prolonged release of somatotropin comprising the somatotropin, a tocopherol component, and an assistant delaying agent |
US5620700A (en) * | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
JP3220331B2 (ja) | 1993-07-20 | 2001-10-22 | エチコン・インコーポレーテツド | 非経口投与用の吸収性液体コポリマー類 |
WO1995003009A1 (fr) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Methode de traitement de la degenerescence maculaire |
WO1995003807A1 (fr) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Traitement de la degenerescence maculaire due au vieillissement |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
SE9403160D0 (sv) * | 1994-09-21 | 1994-09-21 | Pharmacia Ab | Method and means for prevention and treatment of secondary cataract |
US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
ES2158611T3 (es) * | 1996-12-20 | 2001-09-01 | Alza Corp | Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion. |
US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
US6733767B2 (en) | 1998-03-19 | 2004-05-11 | Merck & Co., Inc. | Liquid polymeric compositions for controlled release of bioactive substances |
EP1087977B1 (fr) | 1998-06-15 | 2003-01-08 | Takeda Chemical Industries, Ltd. | Derives de thienodipyridine, production et utilisation |
ID28460A (id) * | 1998-07-08 | 2001-05-24 | Lipogenics Inc | Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol |
US6174540B1 (en) | 1998-09-14 | 2001-01-16 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated caster oil |
US6537566B1 (en) | 1999-03-11 | 2003-03-25 | John Alton Copland | Compositions and methods for the non-invasive treatment of uterine fibroid cells |
CA2366884A1 (fr) * | 1999-04-02 | 2000-10-12 | Washington State University Research Foundation | Administration amelioree de composes de vitamine e au niveau tissulaire et infracellulaire |
DE19923551A1 (de) * | 1999-05-21 | 2000-11-30 | Lohmann Therapie Syst Lts | Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht |
MXPA01011981A (es) | 1999-05-24 | 2003-09-04 | Sonus Pharma Inc | Vehiculo de emulsion para farmacos poco solubles. |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US20010049366A1 (en) * | 2000-02-09 | 2001-12-06 | Alcon Universal Ltd. | Topical solution formulations containing an antibiotic and a corticosteroid |
ATE363271T1 (de) | 2000-03-17 | 2007-06-15 | Avocet Polymer Technologies In | Verfahren zur verbesserung der grösse und des aussehens einer wunde |
KR100365678B1 (ko) * | 2000-03-24 | 2002-12-26 | 주식회사 엘지생명과학 | 주사능이 개선된 소마토트로핀 조성물 |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US20050101517A1 (en) * | 2000-08-23 | 2005-05-12 | Henrick De Nijs | Novel testosterone ester formulation for human use |
US6827931B1 (en) * | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
CA2429998C (fr) | 2000-11-29 | 2012-01-17 | Oculex Pharmaceuticals, Inc. | Procedes permettant de reduire ou prevenir le rejet de greffe dans l'oeil et implants intraoculaires utilises a cet effet |
WO2002060439A1 (fr) * | 2001-01-29 | 2002-08-08 | Takeda Chemical Industries, Ltd. | Medicaments analgesiques et anti-inflammatoires |
US6653992B1 (en) * | 2001-02-28 | 2003-11-25 | Varian Medical Systems, Inc. | Method and circuit for reduction of correlated noise |
AU2002364051A1 (en) * | 2002-01-24 | 2003-09-02 | Children's Medical Center Corporation | Anti-cancer combination and use thereof |
US7074426B2 (en) | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
US6960346B2 (en) * | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
US6855340B2 (en) * | 2002-05-24 | 2005-02-15 | Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
ES2321505T3 (es) * | 2002-07-31 | 2009-06-08 | Alza Corporation | Composiciones de deposito de polimero multimodal inyectables y empleo de las mismas. |
WO2004026281A2 (fr) * | 2002-09-23 | 2004-04-01 | Microchips, Inc. | Systemes de liberation osmotique a microreservoirs et dispositif d'echantillonnage a microtubes |
US20050143363A1 (en) * | 2002-09-29 | 2005-06-30 | Innorx, Inc. | Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases |
US6653288B1 (en) | 2002-09-30 | 2003-11-25 | Virbac S.A. | Injectable anthelmintic compositions and methods for using same |
RU2355385C2 (ru) | 2002-11-06 | 2009-05-20 | Алза Корпорейшн | Композиции пролонгированного действия с контролируемым высвобождением |
US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
US7399784B2 (en) * | 2002-11-26 | 2008-07-15 | Children's Hospital & Research Center At Oakland | Tocopherol and tocotrienol anti-obesity medicaments |
EP1572216A1 (fr) * | 2002-12-20 | 2005-09-14 | Control Delivery Systems, Inc. | Compositions de steroides pour utilisation intraoculaire |
JP2007525429A (ja) * | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー,インコーポレイテッド. | 細胞スケジュール依存性抗癌剤のための処方 |
US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
ATE401054T1 (de) * | 2004-06-04 | 2008-08-15 | Camurus Ab | Flüssige depotformulierungen |
NZ553369A (en) * | 2004-09-17 | 2010-11-26 | Durect Corp | Sustained local anesthetic composition containing preferably a sugar ester such as saib |
-
2005
- 2005-09-27 JP JP2007534731A patent/JP5682991B2/ja active Active
- 2005-09-27 AU AU2005292145A patent/AU2005292145C1/en active Active
- 2005-09-27 CN CN201010169341.3A patent/CN101890167B/zh active Active
- 2005-09-27 KR KR1020137028317A patent/KR101506925B1/ko active IP Right Grant
- 2005-09-27 KR KR1020077009976A patent/KR101341359B1/ko active IP Right Grant
- 2005-09-27 MX MX2011005101A patent/MX344532B/es unknown
- 2005-09-27 WO PCT/US2005/034822 patent/WO2006039336A2/fr active Application Filing
- 2005-09-27 CN CN2005800397759A patent/CN101060831B/zh active Active
- 2005-09-27 BR BRPI0516830-9A patent/BRPI0516830A/pt not_active Application Discontinuation
- 2005-09-27 NZ NZ554426A patent/NZ554426A/en unknown
- 2005-09-27 MX MX2007003968A patent/MX2007003968A/es active IP Right Grant
- 2005-09-27 US US11/236,426 patent/US7906136B2/en active Active
- 2005-09-27 CA CA2582096A patent/CA2582096C/fr active Active
- 2005-09-27 EP EP05804034A patent/EP1793803B1/fr active Active
- 2005-09-27 EP EP17150503.5A patent/EP3173072A1/fr not_active Withdrawn
- 2005-09-27 EP EP12000880A patent/EP2452670A1/fr not_active Ceased
- 2005-09-27 MX MX2016016614A patent/MX366832B/es unknown
-
2006
- 2006-03-27 MY MYPI20061332A patent/MY167123A/en unknown
-
2007
- 2007-12-06 HK HK07113369.9A patent/HK1107672A1/xx unknown
-
2011
- 2011-05-17 AU AU2011202288A patent/AU2011202288B2/en active Active
-
2012
- 2012-01-18 JP JP2012008366A patent/JP2012072196A/ja not_active Withdrawn
-
2014
- 2014-05-30 JP JP2014112629A patent/JP6342716B2/ja active Active
-
2016
- 2016-09-05 JP JP2016172955A patent/JP2016199596A/ja active Pending
-
2018
- 2018-03-16 JP JP2018049492A patent/JP6650479B2/ja not_active Expired - Fee Related
- 2018-06-07 JP JP2018109586A patent/JP2018135400A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1107672A1 (en) | Conveniently implantable sustained release drug compositions | |
IL188964A0 (en) | Sustained drug release composition | |
HK1200092A1 (en) | Sustained release formulations | |
IL177566A0 (en) | Pharmaceutical formulations | |
EP1765283A4 (fr) | Compositions pharmaceutiques | |
GB0409703D0 (en) | Pharmaceutical compositions | |
EP1765385A4 (fr) | Composition vaccinale à libération prolongée | |
ZA200705530B (en) | Sustained release pharmaceutical formulations | |
GB0408308D0 (en) | Pharmaceutical compositions | |
GB0426301D0 (en) | Pharmaceutical formulations | |
EP1802346A4 (fr) | Composition pharmaceutique à libération prolongée | |
EP1714643A4 (fr) | Preparation pour liberation soutenue | |
EP1753405A4 (fr) | Preparation pharmaceutique a liberation lente | |
EP1805154A4 (fr) | Compositions pharmaceutiques | |
EP1714648A4 (fr) | Medicament de combinaison | |
IL180316A0 (en) | Quinolone-containing medicinal composition | |
IL180487A0 (en) | Medicament | |
GB0416397D0 (en) | Pharmaceutical formulations | |
GB2420976B (en) | Therapeutic implant | |
GB0406048D0 (en) | Drug formulations | |
EP1747205A4 (fr) | Compositions pharmaceutiques | |
GB0407351D0 (en) | Pharmaceutical compositions | |
GB0411502D0 (en) | Pharmaceutical compositions | |
GB0400971D0 (en) | Pharmaceutical compositions | |
GB0426942D0 (en) | Medicament |